Anavex Life Sciences Corp. (0HFR.L)
- Previous Close
3.4500 - Open
3.3800 - Bid --
- Ask --
- Day's Range
3.3800 - 3.4500 - 52 Week Range
3.3800 - 10.4460 - Volume
152 - Avg. Volume
7,784 - Market Cap (intraday)
1.984M - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5790 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
www.anavex.com40
Full Time Employees
September 30
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0HFR.L
Performance Overview: 0HFR.L
Trailing total returns as of 4/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0HFR.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0HFR.L
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.70%
Return on Equity (ttm)
-31.88%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-43.16M
Diluted EPS (ttm)
-0.5790
Balance Sheet and Cash Flow
Total Cash (mrq)
143.76M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-17.68M
Company Insights: 0HFR.L
0HFR.L does not have Company Insights